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Abstract: Heat shock proteins (HSPs) constitute a large family of conserved proteins acting as
molecular chaperones that play a key role in intracellular protein homeostasis, regulation of apoptosis,
and protection from various stress factors (including hypoxia, thermal stress, oxidative stress).
Apart from their intracellular localization, members of different HSP families such as small HSPs,
HSP40, HSP60, HSP70 and HSP90 have been found to be localized on the plasma membrane of
malignantly transformed cells. In the current article, the role of membrane-associated molecular
chaperones in normal and tumor cells is comprehensively reviewed with implications of these proteins
as plausible targets for cancer therapy and diagnostics.
Keywords: heat shock proteins; HSP90; GRP96; HSP70; GRP78; HSP60; HSP40; HSP27; calreticulin;
targeted diagnostics and therapy
1. Introduction
Heat shock protein (HSP) families consist of constitutive and stress-inducible members such
as HSPB (small HSP), DNAJ (HSP40), HSPA (HSP70), HSPC (HSP90), HSPH (HSP110) and their
related chaperokines HSPD/E (HSP60/HSP10) and CCT (TRiC) [1]. HSPs reside in the following three
intracellular compartments and are also localized extracellularly where they fulfill various tasks:
(1) cytosol (including various intracellular organelles (e.g., mitochondria); (2) nucleus; (3) and plasma
membrane. Cytosolic chaperones play important roles in intracellular protein homeostasis including
folding, unfolding and transport of denatured proteins and regulation of apoptosis. Upon stress such
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as hyperthermia, ionizing radiation, hypoxia, acidosis, and nutrient deprivation [2,3], their synthesis is
rapidly upregulated by an activation of different heat shock factors (HSFs) in normal and tumor cells,
although tumor cells per se exhibit elevated HSP levels already under physiological conditions due to
their challenging microenvironment. A high HSP expression in various types of cancer cells is associated
with tumor progression and resistance to anti-cancer therapies (including radio-/chemotherapies) [4].
Furthermore, upon stress (e.g., anoxia and hyperthermia) HSPs rapidly translocate into the nucleus,
where they support their synthesis in an autocrine loop [5–7]. Extracellular HSPs were reported to
play a role in both innate and adaptive anti-cancer immunity, implicating their possible application
for development of immunotherapeutic approaches [8,9]. Thus, Hsp70 and Hsp90 proteins were
shown to stimulate anti-tumor responses by facilitating cross-presentation of antigenic peptides via
major histocompatibility complex (MHC) class I molecules, with subsequent induction of a CD8+ T
cell-mediated immune response [9]. Furthermore, molecular chaperones of the HSP70 family can
enhance cytolytic, migratory and proliferative capacities of natural killer (NK) cells even in the absence
of immunogenic peptides [8,9].
Apart from their intracellular localization, various representatives of the major HSP families
are reported to be expressed on the plasma membrane of cells [10–14]. Comprehensive profiling of
the cell surface proteome of different tumor cell types (e.g., A549 lung adenocarcinoma, SH-SY5Y
neuroblastoma, LoVo colon adenocarcinoma, Sup-B15 acute lymphoblastic leukemia, CX colon
carcinoma and SKOV3 ovarian tumor cells) revealed the presence of numerous chaperones including
HSP70, GRP75, GRP78, HSP60, HSP54, HSP27, and protein disulfide isomerase (PDI) on the
plasma membrane [10,15]. Subsequent studies demonstrated the presence of other chaperones
including HSP90, GRP96, HSP40, and calreticulin on tumor cell membranes [16–18]. Residents
of the endoplasmatic reticulum (ER) (HSP47, GRP78, binding immunoglobulin protein (BiP), ERP57,
PDI, GRP96, and calreticulin) gained relocalization signals (e.g., a KDEL sequence at the carboxy
terminus) [17] or post-translational modification, which enables their transport to the plasma membrane
(reviewed in [19]). However, for cytosolic HSPs (HSP70, HSP60, and HSP40), the exact mechanisms of
protein transport, translocation through the membrane, and anchorage in the plasma membrane remain
to be determined. In the current review, the role of cell surface-bound HSPs on tumor cells is discussed
with respect to their possibility for development of novel diagnostic and therapeutic tools in oncology
as well as their potential function in tumor progression and resistance to anti-cancer therapies.
2. HSP70 Family
The (1) inducible form of Hsp70 (HSPA1A) (but not the constitutive form, Hsc70) and (2) the
ER-localized glucose-regulated protein 78 (GRP78) (HSPA5) (Figure 1) have been found to be localized on
the plasma membrane of a variety of tumor cell types including primary glioblastomas [20], squamous
cell carcinoma of the head and neck (HNSCC) and non-small-cell lung carcinoma (NSCLC) [21,22],
human oral dysplasia and squamous cell carcinoma [23], colorectal and gastric cancer [24], pancreatic
carcinoma [25], osteosarcoma [26], and acute myelogenous leukemia [25,27]. The transport of
cytosolic Hsp70 to the plasma membrane occurs most likely via non-classical, vesicular mechanisms,
since inhibitors of the post-Golgi membrane traffic by monensin or brefeldin A (BFA) do not
impede the expression of membrane-bound Hsp70 (mHsp70) [28,29]. In a more recent study by
Evdokimovskaya et al., application of BFA did not interfere with the secretion of Hsp70 (as well
as Hsc70) by baby hamster kidney (BHK-21) cells, thus indicating a non-classical pathway of
chaperone release [30].
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Figure 1. Membrane-associated heat shock proteins and their role in tumor pathogenesis.
Intriguingly, in patients with gastric and colon carcinomas mHsp70 expression correlated with
an improved overall survival (OS), whereas a negative association was reported in squamous cell
carcinoma and lower rectal cancer [24]. It is speculated that these contradictory results may be
attributed to differences in the route of metastasis in these tumors or the complex role of Hsp70 in
tumorigenesis. On the one hand, the hepatic route of metastasis of gastric and colon carcinomas
might enable liver-residing CD56+ NK cells to deplete mHsp70+ tumor cells, and thereby might
improve clinical outcome. On the other hand, mHsp70 was proposed to mediate a protective
role against ionizing radiation by stabilizing lysosomal membranes (via enhancing the activity
of acid spingomyelinase) [15,31,32], which protects tumor cells from lysosome-dependent cell
death [33]. It has been shown that mHsp70 participates in non-classical secretory pathways [34,35]
and facilitates clathrin-independent endocytosis [36]. An interaction of lysin-rich domains in the
substrate-binding domain of Hsp70 directs Hsp70 monomers in an anti-parallel orientation [37],
which facilitates dimerization, interaction with other co-chaperones (Hsp40, Hsp90, Hop) and HSP
client proteins [38]. Presumably, post-translational modifications, especially in the substrate-binding
domain (SBD), may also regulate Hsp70–lipid interactions, but further studies are required to prove
this hypothesis [39–43]. Depletion of the C-terminal helical lid subdomain (∆LSBD641 variant without
the linker) also impairs Hsp70 oligomerization [37], which counteracts mHsp70-mediated facilitation of
endocytosis [36]. In a B16/F10 mouse melanoma model, already 60 min following intravenous injection
of rhHsp70-I123 the radiolabeled chaperone accumulated inside the tumor [44]. Cellular uptake of
Hsp70 itself may also require its oligomerization on the cell surface [36,44–49].
Epitope mapping of the Hsp70-specific antibody cmHsp70.1 (aa 453–460), which detects cell
surface bound Hsp70 on viable tumor cells with intact plasma membrane [50], revealed that the epitope
of Hsp70 exposed on the plasma membrane of tumor cells is part of the oligomerization domain.
Therefore, a 14-mer peptide TPP (aa 450–463) covering this region selectively binds to mHsp70+ tumor
cells and can also become internalized. Based on these findings, a fluorescence and radiolabeled
TPP peptide tracer has been developed that specifically targets mHsp70+ tumors in vitro and in
tumor mouse models [51,52]. More recent studies demonstrated a role of mHsp70 in the formation of
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cell-to-cell connections via tunneling nanotubes (TNTs) in a 100 nm range, employing live-cell STED
nanoscopy [53]. TNTs originate from cholesterol-rich microdomains, where mHsp70 co-localizes with
the tumor-specific glycosphingolipid globoyltriaoslyceramide Gb3/CD77 [54].
Gb3, predominantly found in cholesterol-rich microdomains (CRMs), is overexpressed on the
surface of tumor cells, as compared to corresponding normal cells [54]. Among other effects, a depletion
of cholesterol by methyl-β-cyclodextrin reduces the amount of Gb3 concomitant with the amount of
mHsp70 from the plasma membrane of tumor cells. Furthermore, in vitro experiments employing
artificial liposomes consisting of PC/SM/Chol/Gb3 at a ratio of 17/45/33/5 confirmed a specific interaction
of recombinant Hsp70 specifically with Gb3-containing vesicles [54]. Presumably, the interaction of Gb3
with the ATPase domain of Hsp70 in CRMs resembles the association of Hsp70 with 3’-sulfogalactolipid
(SGL) [55]. Employing the truncated and mutagenized polymerase chain reaction products of the
N-terminal Hsp70 fragments (NBD) including residues 318–387 (the base of the ATP-binding cleft)
has shown that particularly Arg (342) and Phe (198) are crucial for binding of SGL [55]. Furthermore,
time-resolved high-resolution AFM images as well as mutational analysis have proven the interaction
of NBD with lipids [33,36,42,56]. In the study of Mahalka et al., it was proposed that Hsp70 can directly
bind to membranes via insertion into the bilayers by the tryptophan residues Trp-580 in the SBD and
Trp-90 in NBD [56].
Upon hypoxia stress or mild heat shock, mHsp70 co-localizes with the non-raft lipid component
phosphatidylserine (PS) on the surface of tumor cells [57,58]. Presumably, the translocation of Hsp70
from the cytosol to the outer leaflet could be assisted by flipping of PS from the inner to the
outer leaflet, although further experiments for elucidating this mechanism are required. A direct
interaction of recombinant Hsp70 with PS was proven in artificial unilamellar phosphatidylcholine/
phosphatidylserine (PC/PS) liposomes at different PC/PS ratios ranging from physiological ratios
of 8:2 to 2:8, in which the highest interaction was observed in liposomes with the highest PS
content. Charge-dependent, non-specific interactions of Hsp70 with lipids could be excluded since
Hsp70 did not incorporate into phosphatidylcholine/phosphatidylglycerol (PC/PG, ratio 8:2) liposomes
with identical charge. An interaction of exogenously administered Hsp70 with mHsp70 of stressed
tumor cells can also occur by a protein–protein interaction via the extracellular-localized oligomerization
domain of Hsp70 although further experiments are required to prove this hypothesis [36,42]. The binding
of exogenous Hsp70 to PS at high concentrations (10–50 µg/mL) resulted in a concentration-dependent
reduction in tumor cell viability (EC50 of Hsp70 = 55 µg/mL) and proliferation, which in turn enhanced
the radiosensitization of hypoxic cells [57]. Screening the PS moieties with annexin V decreased the
toxic effects of Hsp70 or Hsc70 that were added into the culture medium [59]. Subsequent experiments
employing atomic force microscopy (AFM) have proven an association of recombinant Hsp70
with planar lipid monolayers at a dipalmitoylphosphatidylcholine/dipalmitoylphosphatidylserine
(DPPC/DPPS) ratio of 80:20 mol% [60]. Presumably, an electrostatic Hsp70 interaction with lipids is
essential for the initial docking with the membrane and that anchoring is driven by the alignment of
protein domains with the dipalmitoyl chains of DPPS [60,61]. Further in vitro experiments confirmed
an association of Hsp70 with PS and Gb3 [62–64].
Apart from heat shock and hypoxia several other stress factors including γ-irradiation and
UV light [65–67], anti-inflammatory agents [68], cytostatic drugs (e.g., taxol, vincristinsulfate) [69],
membrane-interacting alkyl-lysophospolipids [70], and HDAC inhibitors (antibiotic depsipeptide
FR901228) [71] result in an upregulation of cytosolic and mHsp70 on tumor cells. Furthermore,
exogenously administered recombinant human Hsp70 induces the relocation of its cytosolic form to
the plasma membrane after internalization, and thereby increases the level of mHsp70 [48].
Membrane-bound Hsp70 also plays an important role in tumor immunosurveillance, serving as
an antigen for the adaptive and innate immune system [9,29,72]. Hsp70-chaperoned tumor peptides
presented on the plasma membrane of tumor cells are recognized by αβ and γδ T-lymphocytes [73,74].
As shown by Wei et al., a subsequent incubation of target cells with anti-Hsp70 antibody abrogated the
cytotoxicity of OK432 (streptococcal preparation)-activated γδ T-lymphocytes [73]. In line with these
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findings, autologous polymorphonuclear neutrophils (PMNs) expressing mHsp70 are recognized and
lysed by γδ T-lymphocytes, and thereby protect the host cells from inflammation-induced damage [75].
Furthermore, cells undergoing apoptotic cell death show an upregulated mHsp70 expression in the
context with PS. Macrophages recognize PS on the outer leaflet as an “eat-me” signal [76–78].
Further studies have demonstrated that mHsp70 on tumor cells, even in the absence of
HSP-chaperoned peptides, can be recognized by natural killer (NK) cells, particularly after ex vivo
stimulation with Hsp70 peptide TKD and low-dose IL-2 [72,79,80]. Subsequent antibody blocking
experiments suggest that the heterodimeric C-type lectin receptor CD94 in complex with NKG2C
on NK cells serves as a potential receptor for mHsp70. A co-incubation of NK cells with TKD/IL-2
resulted in significant upregulation of the CD94 density on NK cells that was accompanied by
an increased cytolytic activity mediated by an upregulated granzyme B production [81] against
mHsp70+ tumor cells [82,83]. Preclinical studies employing human pancreatic (Colo357) and colon
(CX2) carcinoma-bearing SCID/beige mice after intravenous injection of ex vivo TKD/IL-2-stimulated
human NK cells have further proven the therapeutic potency of NK cells with respect to tumor growth
control and reduction in liver metastasis [84,85]. Vice versa, the importance of mHsp70 for eliciting NK
cell-based anti-tumor activity was demonstrated after treatment of tumor cells with vitamin A derivates,
such as 13-cis retinoic acid (13-RA) or all-trans retinoic acid (ATRA), which are known to support
redifferentiation of tumor towards normal cells concomitant with a loss in the mHsp70 expression [86].
A long-term co-incubation of tumor cells with these agents at non-toxic concentrations resulted in
a significant decrease in the mHsp70 expression density, which in turn reduced the sensitivity of these
redifferentiated cells to the cytolytic activity of NK cells [86].
In a phase I clinical trial, the safety, tolerability and feasibility of ex vivo TKD/IL-2-stimulated
autologous NK cells were proven in 12 patients with advanced tumor stages (colorectal cancer, n = 11;
NSCLC, n = 1) [87]. Based on these promising clinical data, a randomized multicenter phase II clinical
trial (EudraCT 2008-002130-30) was started in patients with non-metastasized but locally advanced
(IIIA and IIIB) NSCLC in combination with radiochemotherapy [88].
An interesting approach to restore tumor cell sensitivity towards cytolytic activity of NK cells
was introduced by Sapozhnikov et al., employing the barnase:barstar pair for a targeted delivery of
full-length Hsp70 or the 16 kDa C-terminal Hsp70 fragment to the plasma membrane [89]. In the first
module, anti-HER2/neu mini-antibody conjugated with barnase was applied for a selective binding to
the cell membrane of SKOV3 human ovarian adenocarcinoma and human BT-474 breast carcinoma
cells. In a second step, the module barstar-Hsp70 (or its 16 kDa fragment) was attached to the first
module, subsequently stimulating cytotoxic activity of NK cells against cancer cells, in vitro [89].
mHsp70 could be employed for the development of novel diagnostic and therapeutic
(i.e., theranostic) Hsp70-targeting agents and could serve as a biomarker for detection and monitoring
of tumors [90] or virally infected cells. Up-to-date radionuclide-, fluorescence-, nanoparticle-labeled
mHsp70-targeted tools (including full recombinant Hsp70, monoclonal anti-Hsp70 antibodies, antibody
Fab fragments, tumor penetrating peptide (TPP), granzyme B, and anticalines) have been successfully
employed for visualization (MRI, PET, epifluorescence) and therapy in preclinical studies (Table 1). Thus,
several studies demonstrated that mHsp70-targeted nanoparticles could be used for the detection and
therapy of tumors [50–52,67,91]. In a recent study, functionalized nanoparticles with the serine protease
granzyme B (GrB) (GrB-SPIONs) were used as a negative contrast enhancement agent for visualization
of tumors by magnetic resonance imaging (MRI) and a pro-apoptotic therapeutic agent [91].
Another member of the HSP70 family, the ER-localized glucose-regulated protein 78 (GRP78),
was also reported to be expressed on the membrane of tumor cells [10,92–95]. Due to the four
hydrophobic domains capable of forming transmembrane helices localizing both the C- and N-terminal
domains outside the membrane, GRP78 is expressed as a transmembrane protein [95]. In a recent study
by Vig et al., it was demonstrated that GRP78 translocated to the membrane via the anterograde secretory
pathway through Golgi complex, and DNAJC3 protein facilitated this process [96]. Membrane-bound
GRP78 acts as a signaling receptor that, upon binding of its extracellular form sGRP78, initiated
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pro-apoptotic signaling cascades (increasing caspase 3/7 activity), which was accompanied by enhanced
Bax and Chop mRNA expression [96]. Further studies have shown that GRP78 can also regulate the
PI3K/Akt signaling [97,98]. Apart from direct embedding into the lipid bilayer, GRP78 can directly
bind to transmembrane protein complexes and thereby interact with membranes [99].
Membrane-associated GRP78 was reported for hepatocellular carcinoma [100], prostate
cancer [101,102], mammary carcinoma [103,104], lung [105,106] and gastric cancers [107,108].
mGRP78 has been shown to serve as a potential target for tumor-specific therapies (Table 1) [109].
Subsequent studies by Rauschert et al. demonstrated that apart from mGRP78 expressed on the
cell membrane, its post-transcriptionally modified 82 kDa glycosylated isoform, termed GRP78SAM-6,
is exposed particularly on the plasma membrane of a wide range of cancer types, but not on
normal cells [109].
As reported by Papalas et al., expression of GRP78 in melanoma patients correlated with patient
survival and invasive potential of the tumor [110]. Previously, it was demonstrated that GRP78 serves
as a signaling receptor for activated α2-macroglubulin, microplasminogen, and plasminogen kringle 5,
which functions as a receptor for angiogenic peptides. Furthermore, GRP78 is also involved in the
MHC class I antigen presentation cascade [111,112]. Thus, binding of α2-macroglubulin to mGRP78
induces mitogenic signaling and tumor cell proliferation and increases metastatic spread [113,114].
Furthermore, it plays an important role for viral entry of dengue fever and coxsackie B virus.
Subsequent studies by Arap et al. demonstrated that synthetic chimeric peptides designed from
GRP78 binding motifs (i.e., WIFPWIQL and WDLAWMFRLPVG), fused to the programmed cell
death-inducing sequence, can decrease tumor progression in preclinical models of breast and prostate
cancer [115]. Application of monoclonal antibodies directed against the COOH-terminal domain of
GRP78 also shows a pro-apoptotic activity (via upregulation of p53) in 1-LN and DY145 prostate cancer
cells and A375 melanoma cells [116]. However, mGRP78 association was also reported for normal
cells including macrophages, fibroblasts and endothelial cells, indicating possible off-target effects
induced by anti-GRP78 therapies [112,117–119]. Indeed, in the study by Katanasaka et al., the authors
demonstrated that GRP78-targeted WIFPWIQL-modified liposomes containing doxorubicin, efficiently
bound to colon carcinoma cells and HUVEC endothelial cells [117]. To reduce unfavorable side effects
of anti-GRP78 antibodies, a human monoclonal IgM antibody (SAM-6) derived from a gastric cancer
patient was tested which is recognizing a cancer-specific GRP78–O-linked carbohydrate moiety [109].
Application of the SAM-6 IgM antibody resulted in a tumor-specific cell death via lipoptosis [120,121].
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3. HSP90 Family
For the HSPC (HSP90) family, a membrane association was reported for two representatives:
(1) Hsp90 (isoforms Hsp90α and Hsp90β), and (2) ER resident GRP96 (Figure 1, Table 2). In a study by
Zhang et al. using surface plasmon resonance (SPR), it was shown that Hsp90 interacts with unsaturated
phospholipids (i.e., POPS and POPG), and the observed affinity was higher when negatively charged
lipids were involved (as compared to the zwitterionic lipids) [132]. Upon interaction with lipids,
the α-helical structure of Hsp90 was increased, which may play a role for protein docking in the
membrane. Addition of cholesterol to the lipid vesicles further enhanced the binding capacity of
Hsp90. However, above a certain level of cholesterol (up to 50% of lipid composition) the association of
Hsp90 was abrogated [132]. Presumably, localization of Hsp90 in the plasma membrane could increase
its rigidity and integrity, which in turn protects cancer cells from various stress factors (including
thermal stress) [132,133]. Indeed, for other HSPs (e.g., Hsp17), an association with the membrane
resulted in a stabilization of the bilayer and a reduction in the membrane fluidity, thus providing
thermotolerance and restoration of membrane functionality [11,12,134–136]. In a recent study by
Li et al., it was demonstrated that Hsp90AA1 interacts with membrane phospholipids at high affinities
not only via electrostatic interactions, but also by embedding its C-terminus into the bilipid layer
which is accompanied with a conformational change of the protein (as shown by far-UV circular
dichroism) [137]. Insertion of full-length Hsp90AA1 or its truncated form (Hsp90AA1-CTD) into
membranes improved membrane integrity and induced thermotolerance in Escherichia coli (E. coli) [137].
A similar stabilizing role upon interaction with membrane phospholipids was described for Hsp90B1
from Anas platyrhnchos (ApHsp90B1) [138]. Apart from the C-terminus, the conserved amphipathic
helix of Hsp90 was also found to play a role in the interaction of Hsp90 with membranes, and thereby
promotes its exosomal release [139].
In addition to interactions with phospholipids, Hsp90 also has been found to be associated with
lipid rafts in membranes [140]. Thus, the depletion of cholesterol results in the dissociation of Hsp70
and Hsp90 from lipid rafts [140].
An association of Hsp90 with the plasma membrane was shown for melanoma metastasis, but not
for melanocytic lesions [141]. Additionally, mHsp90 upregulation, particularly the inducible isoform
Hsp90α but not Hsp90β, on tumor cells was reported for fibrosarcoma HT-1080 and MDA-MB231 triple
negative breast adenocarcinoma cells [16]. Hsp90α interacted with matrix metalloproteinase 2 (MMP2)
in the extracellular space. Subsequent inhibition of Hsp90α employing anti-Hsp90 antibodies or
scFvs significantly inhibited tumor cell invasion [16]. However, in another study employing HT-1080
and human A172 glioblastoma cells, the authors indicated that both Hsp90 isoforms, Hsp90α and
Hsp90β, play a role for the motility of tumor cells. The cell surface heparan sulfate proteoglycans have
been shown to play a role for the membrane expression of Hsp90 [142]. A decrease in sulfonation of
heparan sulfates by heparinase I/III or heparin reduces the levels of both isoforms and subsequently
inhibited cell motility [143]. An involvement of mHsp90 for tumor cell motility was further proven
by small-molecule DMAG-N-oxide, a cell-impermeable 17DMAG-derived Hsp90 inhibitor [143].
The anti-invasive and anti-migratory activities of DMAG-N-oxide were demonstrated for different
tumor cells types such as T24 bladder cancer, PC3M prostate cancer, and B16 melanoma cells in vitro
at µM levels. Precise analysis revealed that mHsp90 might be involved in integrin signaling, which
in turn influences focal adhesion. Subsequent in vivo studies showed that application of either
DMAG-N-oxide or anti-Hsp90 antibody SPA830 reduced lung colonization after i.v. injection of B16
melanoma cells [143]. Employment of another monoclonal antibody 4C5 also reduced B16F10 melanoma
metastasis in mice [144]. Furthermore, GA conjugated to cell-impermeable agarose beads could inhibit
cell migration [16]. In the study by Cid et al., expression of mHsp90 was shown for the human
neuroblastoma cells NB69 [145]. Furthermore, upregulation of mHsp90 was higher in undifferentiated
spherical neuroblastoma cells as compared to more differentiated flattened cells [145]. Expression of
mHsp90 was also shown to be important for the migration of neuronal cells, thus indicating a role of the
protein in the development of the nervous system [146]. Additionally, it was reported that mononuclear
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cells obtained from patients with systemic lupus erythematosus also express mHsp90 [147]. Intriguingly,
as shown by Li et al., extracellular Hsp90α can also regulate human fibroblast cell motility via the
HIF-1 pathway and thereby influences wound healing in mice [148].
Another protein Grp96, the ER homologue of Hsp90, was shown to be associated with the
plasma membrane and plays a role in the induction of immune responses [17]. mGrp96 expression
was reported to be associated with tumor malignancy in certain tumor types [17,149,150]. mGrp96
can bind to the metalloproteinase domain with thrombospondin type 1 motifs 9 (pro-ADAMTS9),
and a metalloprotease pro-a disintegrin-like domain that results in enhanced tumor progression and
angiogenesis [151–153]. Intriguingly, various infections including E. coli K1 and Listeria monocytogenes
also upregulated the expression of mGrp96 [154–156]. Furthermore, mGrp96 expression was reported
for murine immature thymocytes [157]. In a study by Hou et al., it was shown that mGrp96-targeted
siRNA could significantly inhibit tumor growth and increase the overall survival of animals [158].
mGrp96 was shown to interact with HER2, thus facilitating the HER2 dimerization, with subsequent
promotion of tumor cell proliferation. Inhibition of conformational Grp96 changes by an α-helix
peptide decreases the HER2 dimerization, with subsequent inhibition of tumor cell growth, in vitro
and in vivo [159]. Inhibition of mGrp96 by using anti-Grp96 monoclonal antibodies induces apoptosis
and decreases tumor growth, in vivo [160].
4. Other Membrane-Associated HSPs
Among other HSPs, Hsp25 (murine homolog of human Hsp27) is known to be present on the
plasma membrane of tumor cells (Figure 1) [161]. Previous studies demonstrated that large parts
(particularly α-crystallin domain) of HSPB1 (Hsp27) and HSPB5 (αB-crystallin) are embedded in
liposomes that contain a variety of phospholipids (i.e., POPS, POPC, and POPG) [162–166]. As shown
by Bausero et al., high mHsp25 expression on 4T1 mammary carcinoma cells was associated with
tumor progression and an increased metastatic spread into the lung in an o.t. mouse model [167].
Another member of the small heat shock protein family, Hsp22/HspB8, was shown to be expressed
on the surface of human neuroblastoma SK-N-SH cells [168]. Subsequent in vitro studies, employing
lipid vesicles containing phosphatidic acid, phosphatidylinositol or phosphatidylserine, demonstrated
an association of Hsp22 with these lipids, which results in a conformational change of Hsp22 [168].
Hsp60 plasma membrane localization was shown for Daudi cells [169]. Application of two
antibodies (N-20 and K-19) directed towards the amino- and carboxyl-terminus of mHsp60 revealed
the presence of the full-length protein on the cell surface [169]. In another study, the authors
demonstrated that mHsp60, like Hsp70, is associated with lipid rafts as well as with Golgi apparatus
and exosomes [170]. Presumably, various stress-inducing factors could stimulate the expression of
mHsp60. Indeed, in the study by Pfister et al., it was shown that upon heat shock, HUVECs start to
present mHsp60 [171]. Subsequent atomic force microscopy (AFM) employing monoclonal antibody
AbII-13 tethered to AFM tips confirmed the association of mHsp60 with plasma membrane in a patchy
distribution pattern [171]. Another stress (i.e., acute injury) to the cardiac myocytes could also induce
the expression of mHsp60 [172,173]. Presumably, mHsp60 plays a role in the activation of immune
responses. Liver cells infected with intracellular bacterium Listeria monocytogenes exhibited high
levels of mHsp60 [174]. Intriguingly, kinetic profiling of γδ T cell responses most closely matched
that of mHsp60 expression in liver and tumors [175]. Further studies employing secondary human
enterocyte-like Caco-2 cells demonstrated that heat shock (41 ◦C), TNFα, or L. monocytogenes infections
(104–106 CFU/mL) increased the expression of mHsp60 and, as a result, enhances cell adhesion, but not
invasion [175]. Subsequent application of shRNA reversed the adhesive properties of the cells.
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Table 2. Application of the membrane-associated Hsp90 and GRP96 for tumor theranostics.
mHsp90-Targeted Strategies
mHsp90- Targeting Tool Drug and Adjuvant Therapy
Application
Model Administration Results Ref.
Diagnostics Therapy
Anti-Hsp90 monoclonal
antibody 1.5.1 and scFvs (IIIF1,
IH5, IID3, IIC1, IIIG7, IIIC6)
Anti-Hsp90 antibody or scFvs N/A + in vitro HT-1080 fibrosarcomacells N/A





antibody 4C5 N/A +
in vitro MDA-MB453
human breast carcinoma cells N/A
Inhibition of cell invasion











antibody 4C5 N/A +















in vitro T24, B16-luc, PC3M cells
i.v. injection B16 melanoma cells
in Nu/Nu mice
s.c. B16 melanoma in Nu/Nu mice
i.v.
Significant in vitro inhibition of
cell motility and invasion.




mHsp90-Targeting Tool Drug and Adjuvant Therapy
Application








SK-Hep1 cells in nude mice,
s.c. Huh7 cells in nude mice
i.p. Inhibition of tumor growth andlung metastasis [158]
Anti-mGrp96 antibody Anti-mGrp96 antibody N/A + s.c.SK-BR-3, T47D cells in Balb/c mice i.v.
Induction of apoptosis and




peptide p37 N/A +
o.t. T47D, Bcap37 cells in nude
mice i.v. Inhibition of tumor growth [159]
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Calreticulin, another ER-residing stress protein present on tumor cell membranes, was shown
to induce migratory capacity in melanoma cells [18]. Application of anti-calreticulin antibodies
significantly reduced laminin-dependent spreading of melanoma cells. As shown by Elton et al.,
calreticulin interacts with collagen receptors integrin α2β1 and glycoprotein VI in human platelets
that could further support the hypothesis of calreticulin involvement in tumor cell spreading [176].
Calreticulin can bind in a Ca2+-dependent manner to phosphatidylserine (PS) with high affinity
(KD = 1.5 × 10−5 M) [177,178]. Further studies demonstrated that calreticulin can be associated with
lipid rafts in connection with ERP57 [179,180]. Thus, knockdown of ERP57 reduced the expression of
calreticulin on the cell surface and subsequently reduces the phagocytic capacity of dendritic cells,
which in turn decreases immunogenicity, in vivo [180].
Hsp40 (Hdj1) was shown to be associated with Hsp70 on the surface of CX+ colon and Colo+
pancreatic carcinoma cells [15]. Previously, it was shown that Hsp40 is secreted from cells via the
Hsp/Hsc70-dependent exosome pathway [181]. Presumably interaction of the J-domain of Hsp40
with Hsp70 could explain the co-localization of the two proteins on the membrane. Other studies
confirmed the expression of Hsp47 on scirrhous carcinoma of stomach and cervical carcinoma [182,183].
mHsp70+/mHsp40+ tumor cells demonstrated a high radioresistance [15]. However, as shown by
Hebert et al., high levels of mHsp47 on the epidermoid carcinoma cell lines were associated with a low
invasive capacity [184]. In contrast to other data, Yamamoto et al. showed that downregulation of
Hsp47 by microRNA-29a (miR-29a) inhibited tumor cell migration and invasion in cervical squamous
cell carcinoma [183].
Large parts of sHSPs (particularly α-crystallin domain) are embedded into lipid bilayers (a) or
they can be present on the cell surface (b) [162–167]. Calreticulin was described to be associated with
phosphatidylserine (a) or with lipid rafts (b) [18,176–180]. For Hsp60, the presence of full-length
protein on the cell membrane (a) or in association with lipid rafts (b) was reported [169,170].
Hsp70 was shown to be embedded via its NBD in the outer layer of membranes (a), associated
with the membrane surface (b) (presumably in close interaction with the J-domain of Hsp40
protein), and associated with glycosphingolipid Gb3/CD77 in cholesterol-rich microdomains (CRMs)
(c) [33,36,54,56–64]. The ER-localized glucose-regulated protein 70 (GRP78) was shown to be present
on the membrane surface (a) (including association with transmembrane protein complex, surface
glycosylphosphatidylinositol-anchored proteins) or embedded into the lipid bilayer (b) [95,99]. Hsp90
was demonstrated to be present on the membrane surface (a), embedded into the membrane via its
C-terminus (b) or can be associated with lipid rafts (c) [137,138,140]. Grp96, a homologue of Hsp90,
was shown to be expressed on the membrane surface [17,149,150].
5. Conclusions
Apart from their important intracellular functions as molecular chaperones in regulating
intracellular proteostasis, many HSPs have been shown to be expressed on the surface of various types
of solid and hematological malignancies. An increased expression density of mHSPs is associated with
tumor progression, resistance to anti-tumor therapies (e.g., radiochemotherapy), and an enhanced
invasive and metastatic potential. Certain membrane-bound HSPs, including mHsp60, mHsp70 and
their endoplasmatic analogues mGRP78, mGRP96, and membrane calreticulin, were demonstrated
to induce innate and adaptive anti-cancer immunity. Exposure of the intracellular endoplasmatic
chaperones on the plasma membrane of tumor and, in some cases, damaged normal cells, followed
by subsequent activation of immunity represents a possible mechanism of immunologic surveillance
for elimination of malignantly transformed or damaged cells. Some membrane-bound chaperones
(e.g., Hsp70 and Hsp90) could also play a role in tumor cell association with extracellular matrices,
thus influencing cell motility and invasion. Exposure of HSPs on the membrane is directly related to
the composition of the lipid bilayer. Presumably, pharmacological modulation and/or modification
of membrane lipid structures and microdomains could be further exploited in regards to chaperone
expression, which in turn could be used for cancer therapies [185–188]. Expression of HSPs on malignant
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cells makes them a promising target for development of novel diagnostic and therapeutic approaches
in oncology. Several preclinical and clinical studies listed in this review demonstrated their therapeutic
activity in targeted therapies directed against membrane-bound HSPs.
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